불임 검사 시장 : 제품 유형, 검사 유형, 검체 유형, 기술, 최종사용자, 검사 방법별 - 세계 예측(2026-2032년)

The Fertility Testing Market is projected to grow by USD 13.34 billion at a CAGR of 10.33% by 2032.

Fertility testing is moving from a narrowly clinical service into a broader reproductive health diagnostics category that spans ovarian reserve testing, semen analysis, ovulation prediction, hormone panels, genetic screening, and infectious disease testing before assisted reproductive technology. Demand is grounded in measurable need: the World Health Organization reports that infertility affects about 1 in 6 adults globally, making timely diagnosis a public health and family-planning priority.

The market is shaped by delayed parenthood, higher awareness of male-factor infertility, wider use of in vitro fertilization, and growing acceptance of at-home fertility testing. The WHO also recognizes that both male and female factors contribute substantially to infertility, strengthening demand for integrated fertility assessment rather than female-focused testing alone. For healthcare providers, laboratories, and device manufacturers, the strongest opportunities sit at the intersection of clinical accuracy, consumer convenience, digital interpretation, and evidence-based counseling.

Transformative Shifts in the Fertility Testing Landscape

The fertility testing landscape is being reshaped by a shift from episodic infertility workups to earlier, proactive reproductive health assessment. Anti-Mullerian hormone testing, follicle-stimulating hormone panels, luteinizing hormone monitoring, thyroid testing, prolactin testing, semen analysis, and transvaginal ultrasound are increasingly used together to guide clinical decisions and improve referral timing.

Consumer behavior is also changing. At-home sample collection, app-connected ovulation tracking, direct-to-consumer hormone tests, and telehealth consultations are reducing barriers to first-line testing. However, clinical validation, laboratory quality systems, privacy protection, and physician interpretation remain decisive differentiators as regulators and clinicians scrutinize claims tied to fertility prediction. The sector is also moving toward whole-patient reproductive health models that incorporate age, menstrual history, endocrine status, lifestyle risks, sexually transmitted infection screening, and male-factor evaluation.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating fertility testing by improving image analysis, pattern recognition, and personalized risk stratification. In clinical settings, AI-supported tools are being evaluated for sperm morphology assessment, embryo image interpretation, follicle tracking, and prediction models that combine age, ovarian reserve markers, semen parameters, endocrine profiles, and prior treatment history.

The cumulative impact is not replacement of clinicians but better triage, consistency, and workflow efficiency. Adoption will depend on transparent model validation, diverse training datasets, explainable outputs, cybersecurity controls, and alignment with medical device regulations. Companies that pair AI with clinically verified diagnostics can strengthen confidence while reducing time to actionable fertility guidance, especially when algorithmic outputs are positioned as decision support and reviewed within established clinical pathways.

Key Regional Insights

North America remains a high-value fertility testing region because of advanced laboratory infrastructure, broad availability of reproductive endocrinology services, ART reporting systems, and strong use of digital health channels. Europe benefits from established assisted reproduction networks and strong quality expectations, while the European Union's data protection and medical device frameworks are pushing companies toward stronger evidence, traceability, and transparency. Latin America, led by Brazil and Mexico, is advancing through private fertility clinics, urban diagnostic networks, and improving access to reproductive endocrinology services, although affordability and uneven public coverage continue to shape uptake.

Asia-Pacific is expanding rapidly as China, India, Japan, South Korea, and Australia experience delayed childbearing, urbanization, rising infertility awareness, and broader use of diagnostic chains and assisted reproduction services. The Middle East, particularly GCC economies, is investing in specialty care, premium hospitals, and medical tourism-oriented fertility services, with demand influenced by cultural expectations around family formation. Africa shows long-term potential as diagnostic capacity, affordability, laboratory access, and reproductive health infrastructure improve, while current needs remain significant because infertility carries medical, social, and psychological consequences across many communities.

Key Group Insights

ASEAN fertility testing demand is supported by expanding private healthcare, digital health adoption, rising urban incomes, and increasing awareness of delayed conception in metropolitan populations. The GCC is characterized by high investment in premium healthcare, specialist clinics, and medical tourism, making laboratory quality, physician-led counseling, and culturally sensitive reproductive care important competitive factors. The European Union emphasizes regulated diagnostics, patient data protection, evidence-based clinical pathways, and stronger oversight of in vitro diagnostic performance under evolving regulatory requirements.

BRICS economies combine large population bases with uneven access, creating opportunities for scalable, cost-effective hormone testing, semen analysis, ovulation monitoring, and referral-linked fertility assessment. G7 countries lead in advanced reproductive medicine, ART reporting, reimbursement discussions, digital health integration, and AI-enabled diagnostics, while NATO markets overlap with many high-income healthcare systems where resilience, cybersecurity, data governance, and supply-chain assurance are increasingly relevant for diagnostic continuity and patient trust.

Key Country Insights

The United States leads in innovation across at-home fertility testing, ART-linked diagnostics, digital reproductive health, and specialist reproductive endocrinology services, while Canada emphasizes regulated laboratory services, physician-guided care, and equitable access across provinces. Mexico and Brazil are important Latin American growth markets due to private fertility clinic networks, urban diagnostic access, and rising middle-class demand. The United Kingdom, Germany, France, Italy, and Spain benefit from mature reproductive medicine ecosystems, established laboratory standards, and public debate around fertility preservation and assisted reproduction access, whereas Russia maintains demand through large urban healthcare centers and specialist clinics.

China and India represent major volume opportunities supported by population scale, delayed marriage in urban areas, expanding diagnostic chains, and growing awareness of both female and male infertility. Japan and South Korea face persistent low fertility rates, which increases policy and consumer attention on reproductive health, fertility preservation, and earlier diagnostic evaluation. Australia combines advanced clinical standards with strong fertility awareness, well-developed pathology services, and high digital health readiness, while South Korea also stands out for technology adoption in diagnostics and reproductive medicine.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated test menus that connect ovarian reserve, ovulation, endocrine, semen, genetic, infectious disease, and ultrasound-supported results into a coherent fertility assessment. Accuracy, reference ranges, physician-reviewed reporting, and clear limitations should be presented prominently, especially for at-home fertility testing products where consumers may otherwise overinterpret single biomarkers such as anti-Mullerian hormone.

Growth strategies should combine partnerships with fertility clinics, OB-GYN networks, urologists, laboratories, employers, pharmacies, and telehealth platforms. Companies should invest in privacy-by-design architecture, AI governance, culturally relevant education, and affordable testing formats for emerging markets. The most defensible brands will translate complex fertility biomarkers into actionable, ethical, and medically responsible guidance while ensuring that abnormal results trigger timely clinical referral.

Research Methodology

This executive summary is built using secondary research from public health agencies, regulatory bodies, peer-reviewed literature, clinical guidelines, fertility society publications, healthcare infrastructure indicators, and publicly available reproductive health datasets. Key reference points include the World Health Organization's global infertility estimates, national reproductive health statistics, ART reporting systems, diagnostic laboratory standards, and medical device and in vitro diagnostic regulatory guidance.

The research approach triangulates epidemiology, technology adoption, regulatory direction, healthcare access, clinical utility, and regional demand signals. Insights are screened for relevance to fertility testing products and services, including hormone assays, semen analysis, ovulation tests, ultrasound-supported evaluation, genetic screening, infectious disease testing, and AI-enabled interpretation tools. Findings are presented without market sizing, market share, or forecasting to maintain focus on verified qualitative and data-backed industry intelligence.

Conclusion

Fertility testing is becoming a critical entry point for reproductive healthcare as patients seek earlier answers, clinicians require integrated diagnostics, and health systems face sustained demand for assisted reproduction services. The category is expanding beyond clinic-based testing into hybrid models that combine laboratories, digital tools, telehealth, physician interpretation, and at-home sample collection.

Future market leadership will depend on trust. Organizations that demonstrate clinical validity, regulatory discipline, privacy protection, inclusive education, and responsible AI deployment will be best positioned across developed and emerging markets. Fertility testing is no longer only a diagnostic step; it is a strategic foundation for personalized reproductive care, earlier intervention, and more informed family-planning decisions.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Fertility Testing Market, by Product Type

• 7.1. Consumables & Kits
• 7.2. Instruments & Analyzers
• 7.3. Imaging And Diagnostic Systems
• 7.4. Software And Digital Monitoring Solutions
• 7.5. Laboratory Testing Services

8. Fertility Testing Market, by Test Type

• 8.1. Female Fertility Testing
  • 8.1.1. Ovulation Testing
  • 8.1.2. Ovarian Reserve Testing
  • 8.1.3. Reproductive Hormone Testing
  • 8.1.4. Uterine And Fallopian Tube Testing
  • 8.1.5. Cervical Mucus And Vaginal Health Testing
  • 8.1.6. Genetic Fertility Testing
• 8.2. Male Fertility Testing
  • 8.2.1. Semen Analysis
  • 8.2.2. Sperm Function Testing
  • 8.2.3. Sperm DNA Fragmentation Testing
  • 8.2.4. Male Reproductive Hormone Testing
  • 8.2.5. Genetic Fertility Testing
  • 8.2.6. Testicular And Scrotal Imaging
• 8.3. Couple Fertility Test
  • 8.3.1. Compatibility And Joint Fertility Assessment
  • 8.3.2. Preconception Screening
  • 8.3.3. Shared Genetic Carrier Screening

9. Fertility Testing Market, by Sample Type

• 9.1. Urine
• 9.2. Blood
• 9.3. Saliva
• 9.4. Semen
• 9.5. Cervical Mucus
• 9.6. Vaginal Swab
• 9.7. Tissue & Biopsy Samples

10. Fertility Testing Market, by Technology

• 10.1. Lateral Flow Immunoassay
• 10.2. Enzyme-Linked Immunosorbent Assay
• 10.3. Chemiluminescence Immunoassay
• 10.4. Polymerase Chain Reaction
• 10.5. Next-Generation Sequencing
• 10.6. Microfluidics
• 10.7. Imaging-Based Diagnostics
• 10.8. Digital And Sensor-Based Monitoring

11. Fertility Testing Market, by End User

• 11.1. Diagnostic Laboratories
• 11.2. Fertility Clinics
• 11.3. Hospitals
• 11.4. Home Care Users
• 11.5. Research Institutes

12. Fertility Testing Market, by Mode Of Testing

• 12.1. At-Home Testing
• 12.2. Laboratory-Based Testing
• 12.3. Point-Of-Care Testing

13. Fertility Testing Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Fertility Testing Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Fertility Testing Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. CooperSurgical, Inc.
• 17.2. Church & Dwight Co., Inc.
• 17.3. Vitrolife AB
• 17.4. Abbott Laboratories
• 17.5. Danaher Corporation
• 17.6. F. Hoffmann-La Roche Ltd.
• 17.7. Laboratory Corporation of America Holdings
• 17.8. Quest Diagnostics Incorporated
• 17.9. Siemens Healthineers AG
• 17.10. Illumina, Inc.
• 17.11. Revvity, Inc.
• 17.12. Hamilton Thorne Inc.
• 17.13. Thermo Fisher Scientific Inc.
• 17.14. Inito Health Inc.
• 17.15. DiaSorin S.p.A
• 17.16. Guangzhou Wondfo Biotech Co., Ltd.
• 17.17. Reproductive Genetic Innovations, LLC
• 17.18. Easy Healthcare Corporation
• 17.19. Ava AG
• 17.20. ExSeed Health ApS
• 17.21. Fellow Health, Inc.
• 17.22. Fulgent Genetics, Inc.
• 17.23. Give Legacy, Inc.
• 17.24. Medical Electronic Systems Limited
• 17.25. MFB Fertility, Inc.
• 17.26. Quanovate Tech Inc.
• 17.27. QuidelOrtho Corporation
• 17.28. Sandstone Diagnostics, Inc.
• 17.29. SPD Swiss Precision Diagnostics GmbH
• 17.30. viO HealthTech Limited